<p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）在周五发布给客户和投资者的研究报告中，将其目标股价从 48.00 美元上调至 66.00 美元，摩根大通报道。该公司目前对该股票给予 “买入” 评级。摩根大通的目标价表明，相较于公司之前的收盘价，潜在上涨幅度为 29.07%。</p>
<p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
<ul>
<li>分析师们对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
<p>其他一些分析师也对 VERA 发布了报告。Wedbush 将 Vera Therapeutics 的目标股价从 23.00 美元上调至 33.00 美元，并在 12 月 11 日的报告中给予该公司 “中性” 评级。Evercore ISI 在 12 月 8 日的报告中将 Vera Therapeutics 的目标价从 75.00 美元上调至 97.00 美元，并给予该公司 “跑赢大盘” 评级。Pivotal Research 在 12 月 5 日的报告中设定了 Vera Therapeutics 的目标股价为 73.00 美元。高盛集团在周五的报告中将 Vera Therapeutics 的目标股价从 55.00 美元上调至 95.00 美元，并给予该公司 “买入” 评级。最后，摩根大通将 Vera Therapeutics 的目标价从 99.00 美元下调至 96.00 美元，并在周五的研究报告中对该股票设定了 “增持” 评级。十位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 74.83 美元。</p>
<p><strong>查看我们关于 Vera Therapeutics 的最新报告</strong></p>
<h2>Vera Therapeutics 股价上涨 7.2%</h2>
<p>在周五的交易中，纳斯达克 VERA 上涨了 3.45 美元，达到 51.14 美元。该股票的交易量为 560,419 股，而其平均交易量为 1,429,069 股。Vera Therapeutics 的年内最低价为 18.53 美元，年内最高价为 51.19 美元。该股票的 50 日简单移动平均价为 33.47 美元，200 日简单移动平均价为 27.17 美元。该股票的市值为 32.7 亿美元，市盈率为-12.82，贝塔系数为 1.21。该公司的债务与股本比率为 0.19，速动比率为 12.21，流动比率为 12.21。</p>
<p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告每股收益为（1.26 美元），低于市场共识预期的（1.20 美元）0.06 美元。在去年同期，该公司每股收益为（0.85 美元）。卖方分析师预测 Vera Therapeutics 在当前年度的每股收益将为-2.89 美元。</p>
<h2>Vera Therapeutics 的内部买卖情况</h2>
<p>在其他 Vera Therapeutics 的新闻中，董事 Patrick G. Enright 在 12 月 11 日的交易中购买了 5,882 股该股票。该股票的购买均价为每股 42.50 美元，总价值为 249,985.00 美元。交易后，该董事直接持有 5,882 股公司股票，价值 249,985 美元。这笔交易代表了其持股的∞增长。该收购在向 SEC 的法律文件中披露，相关文件可通过此链接访问。此外，高级副总裁 Joseph R. Young 在 11 月 11 日的交易中出售了 15,000 股公司股票。该股票的出售均价为 29.06 美元，总价值为 435,900.00 美元。交易后，该高级副总裁直接持有 47,839 股公司股票，价值 1,390,201.34 美元。这代表了其持股的 23.87% 的减少。该出售的披露信息可在 SEC 文件中找到。公司内部人士持有公司股票的 16.30%。</p>
<h2>机构投资者对 Vera Therapeutics 的看法</h2>
<p>机构投资者和对冲基金最近调整了对该公司的持股。Bollard Group LLC 在第二季度购买了 Vera Therapeutics 的新股份，价值约为 1,509,000 美元。Trexquant Investment LP 在第一季度将其在 Vera Therapeutics 的持股增加了 187.1%。Trexquant Investment LP 现在拥有 62,777 股公司股票，价值 1,508,000 美元，此前在上个季度又购买了 40,913 股。Dynamic Technology Lab Private Ltd 在第一季度获得了 Vera Therapeutics 的新职位，估计价值约为 326,000 美元。Hudson Bay Capital Management LP 在第二季度购买了 Vera Therapeutics 的新职位，估计价值约为 7,044,000 美元。最后，American Century Companies Inc.在第二季度将其在 Vera Therapeutics 的持股增加了 89.3%。American Century Companies Inc.现在拥有 714,428 股公司股票，价值 16,832,000 美元，此前在上个季度又收购了 336,978 股。机构投资者和对冲基金持有公司股票的 99.21%。</p>
<h2>关于 Vera Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Vera Therapeutics 是一家临床阶段的生物技术公司，专注于开发新型免疫疗法，利用自身的调节性 T 细胞治疗自身免疫和炎症性疾病。通过利用专有的蛋白质工程平台，该公司设计了选择性针对 Treg 的细胞因子变体，旨在恢复免疫平衡并提供针对性的、改变疾病进程的效果。其产品管线包括多个针对慢性炎症和自身免疫特征的临床前和临床候选药物。</p>
<p>Vera Therapeutics 成立于 2018 年，总部位于马萨诸塞州剑桥市，与领先的学术和研究机构合作，推动其开发项目。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而非 Vera Therapeutics</li>
<li>初学者如何阅读股票图表</li>
<li>2026 年四只高潜力 ETF：小盘股、太空股票等</li>
<li>成长股：它们是什么，它们又不是些什么</li>
<li>META 在科技下滑中上涨，分析师称赞特朗普的 AI 命令</li>
<li>顶尖生物科技股票：探索创新机会</li>
<li>TL;DR：为什么 Reddit 是新的成长股之王</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Vera Therapeutics 吗？</h2>
<p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Vera Therapeutics 并不在名单上。</p>
<p>虽然 Vera Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VERA

<p>美国银行将 Vera Therapeutics 的目标股价从 48 美元上调至 66 美元，维持 “买入” 评级，表明潜在上涨幅度为 29.07%。其他分析师也调整了他们的目标，普遍给予 “适度买入” 评级，平均目标为 74.83 美元。Vera 的股票上涨了 7.2%，达到 51.14 美元，市值为 32.7 亿美元。还注意到内部交易活动，一位董事购买了股票，一位高级副总裁出售了股票。机构投资者也对该公司的持股进行了调整</p>

<p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) had its price target lifted by Bank of America from $48.00 to $66.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the stock. Bank of America's price objective indicates a potential upside of 29.07% from the company's previous close.</p>
<div class="lb-trans"><p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）在周五发布给客户和投资者的研究报告中，将其目标股价从 48.00 美元上调至 66.00 美元，摩根大通报道。该公司目前对该股票给予 “买入” 评级。摩根大通的目标价表明，相较于公司之前的收盘价，潜在上涨幅度为 29.07%。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师们对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
</div><p>A number of other analysts have also issued reports on VERA. Wedbush boosted their price target on Vera Therapeutics from $23.00 to $33.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, December 11th. Evercore ISI lifted their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, December 8th. Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a report on Friday, December 5th. The Goldman Sachs Group boosted their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the company a &#34;buy&#34; rating in a report on Friday. Finally, JPMorgan Chase &amp; Co. dropped their price objective on shares of Vera Therapeutics from $99.00 to $96.00 and set an &#34;overweight&#34; rating on the stock in a research note on Friday. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $74.83.</p>
<div class="lb-trans"><p>其他一些分析师也对 VERA 发布了报告。Wedbush 将 Vera Therapeutics 的目标股价从 23.00 美元上调至 33.00 美元，并在 12 月 11 日的报告中给予该公司 “中性” 评级。Evercore ISI 在 12 月 8 日的报告中将 Vera Therapeutics 的目标价从 75.00 美元上调至 97.00 美元，并给予该公司 “跑赢大盘” 评级。Pivotal Research 在 12 月 5 日的报告中设定了 Vera Therapeutics 的目标股价为 73.00 美元。高盛集团在周五的报告中将 Vera Therapeutics 的目标股价从 55.00 美元上调至 95.00 美元，并给予该公司 “买入” 评级。最后，摩根大通将 Vera Therapeutics 的目标价从 99.00 美元下调至 96.00 美元，并在周五的研究报告中对该股票设定了 “增持” 评级。十位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 74.83 美元。</p>
</div><p><strong>Check Out Our Latest Report on Vera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Vera Therapeutics 的最新报告</strong></p>
</div><h2>Vera Therapeutics Trading Up 7.2%</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股价上涨 7.2%</h2>
</div><p>NASDAQ VERA traded up $3.45 during trading on Friday, hitting $51.14. The stock had a trading volume of 560,419 shares, compared to its average volume of 1,429,069. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.19. The stock has a 50 day simple moving average of $33.47 and a 200 day simple moving average of $27.17. The stock has a market capitalization of $3.27 billion, a price-to-earnings ratio of -12.82 and a beta of 1.21. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21.</p>
<div class="lb-trans"><p>在周五的交易中，纳斯达克 VERA 上涨了 3.45 美元，达到 51.14 美元。该股票的交易量为 560,419 股，而其平均交易量为 1,429,069 股。Vera Therapeutics 的年内最低价为 18.53 美元，年内最高价为 51.19 美元。该股票的 50 日简单移动平均价为 33.47 美元，200 日简单移动平均价为 27.17 美元。该股票的市值为 32.7 亿美元，市盈率为-12.82，贝塔系数为 1.21。该公司的债务与股本比率为 0.19，速动比率为 12.21，流动比率为 12.21。</p>
</div><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the previous year, the firm posted ($0.85) earnings per share. Sell-side analysts predict that Vera Therapeutics will post -2.89 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告每股收益为（1.26 美元），低于市场共识预期的（1.20 美元）0.06 美元。在去年同期，该公司每股收益为（0.85 美元）。卖方分析师预测 Vera Therapeutics 在当前年度的每股收益将为-2.89 美元。</p>
</div><h2>Insider Buying and Selling at Vera Therapeutics</h2>
<div class="lb-trans"><h2>Vera Therapeutics 的内部买卖情况</h2>
</div><p>In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of the stock in a transaction dated Thursday, December 11th. The stock was purchased at an average price of $42.50 per share, with a total value of $249,985.00. Following the transaction, the director directly owned 5,882 shares of the company's stock, valued at $249,985. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Joseph R. Young sold 15,000 shares of the company's stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the transaction, the senior vice president directly owned 47,839 shares in the company, valued at $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 16.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Vera Therapeutics 的新闻中，董事 Patrick G. Enright 在 12 月 11 日的交易中购买了 5,882 股该股票。该股票的购买均价为每股 42.50 美元，总价值为 249,985.00 美元。交易后，该董事直接持有 5,882 股公司股票，价值 249,985 美元。这笔交易代表了其持股的∞增长。该收购在向 SEC 的法律文件中披露，相关文件可通过此链接访问。此外，高级副总裁 Joseph R. Young 在 11 月 11 日的交易中出售了 15,000 股公司股票。该股票的出售均价为 29.06 美元，总价值为 435,900.00 美元。交易后，该高级副总裁直接持有 47,839 股公司股票，价值 1,390,201.34 美元。这代表了其持股的 23.87% 的减少。该出售的披露信息可在 SEC 文件中找到。公司内部人士持有公司股票的 16.30%。</p>
</div><h2>Institutional Investors Weigh In On Vera Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Vera Therapeutics 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the company. Bollard Group LLC purchased a new stake in shares of Vera Therapeutics during the second quarter worth about $1,509,000. Trexquant Investment LP increased its stake in Vera Therapeutics by 187.1% during the 1st quarter. Trexquant Investment LP now owns 62,777 shares of the company's stock worth $1,508,000 after buying an additional 40,913 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Vera Therapeutics during the first quarter valued at approximately $326,000. Hudson Bay Capital Management LP purchased a new position in shares of Vera Therapeutics in the second quarter valued at approximately $7,044,000. Finally, American Century Companies Inc. boosted its stake in shares of Vera Therapeutics by 89.3% in the second quarter. American Century Companies Inc. now owns 714,428 shares of the company's stock worth $16,832,000 after acquiring an additional 336,978 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该公司的持股。Bollard Group LLC 在第二季度购买了 Vera Therapeutics 的新股份，价值约为 1,509,000 美元。Trexquant Investment LP 在第一季度将其在 Vera Therapeutics 的持股增加了 187.1%。Trexquant Investment LP 现在拥有 62,777 股公司股票，价值 1,508,000 美元，此前在上个季度又购买了 40,913 股。Dynamic Technology Lab Private Ltd 在第一季度获得了 Vera Therapeutics 的新职位，估计价值约为 326,000 美元。Hudson Bay Capital Management LP 在第二季度购买了 Vera Therapeutics 的新职位，估计价值约为 7,044,000 美元。最后，American Century Companies Inc.在第二季度将其在 Vera Therapeutics 的持股增加了 89.3%。American Century Companies Inc.现在拥有 714,428 股公司股票，价值 16,832,000 美元，此前在上个季度又收购了 336,978 股。机构投资者和对冲基金持有公司股票的 99.21%。</p>
</div><h2>About Vera Therapeutics</h2>
<div class="lb-trans"><h2>关于 Vera Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.</p>
<div class="lb-trans"><p>Vera Therapeutics 是一家临床阶段的生物技术公司，专注于开发新型免疫疗法，利用自身的调节性 T 细胞治疗自身免疫和炎症性疾病。通过利用专有的蛋白质工程平台，该公司设计了选择性针对 Treg 的细胞因子变体，旨在恢复免疫平衡并提供针对性的、改变疾病进程的效果。其产品管线包括多个针对慢性炎症和自身免疫特征的临床前和临床候选药物。</p>
</div><p>Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.</p>
<div class="lb-trans"><p>Vera Therapeutics 成立于 2018 年，总部位于马萨诸塞州剑桥市，与领先的学术和研究机构合作，推动其开发项目。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
<li>How to Read Stock Charts for Beginners</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
<li>Growth Stocks: What They Are, What They Are Not</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>TL;DR: Why Reddit is the New Growth Stock to Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Vera Therapeutics</li>
<li>初学者如何阅读股票图表</li>
<li>2026 年四只高潜力 ETF：小盘股、太空股票等</li>
<li>成长股：它们是什么，它们又不是些什么</li>
<li>META 在科技下滑中上涨，分析师称赞特朗普的 AI 命令</li>
<li>顶尖生物科技股票：探索创新机会</li>
<li>TL;DR：为什么 Reddit 是新的成长股之王</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=VERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Vera Therapeutics 吗？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Vera Therapeutics 并不在名单上。</p>
</div><p>While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vera Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

美国银行的分析师表示，Vera Therapeutics（纳斯达克股票代码：VERA）的股价预计将会上涨